Successes, failures, and future prospects of prodrugs and their clinical impact

Management of Statin Intolerance in 2018: Still More Questions Than Answers

(2018) Peter P. Toth et al.   American Journal of Cardiovascular Drugs

Fesoterodine: Pharmacological properties and clinical implications

(2018) Xavier Gamé et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity

(2018) J. Denis et al.   JOURNAL DE MYCOLOGIE MEDICALE

Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity

(2018) M.-P. Ledoux et al.   JOURNAL DE MYCOLOGIE MEDICALE

Strategies for Enhancing the Permeation of CNS-Active Drugs through the Blood-Brain Barrier: A Review

(2018) Isra’ Zeiadeh et al.   MOLECULES

Fostemsavir

(2018) Pedro Cahn et al.   Current Opinion in HIV and AIDS

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas

(2018) Jun Gong et al.   Drug Design Development and Therapy

An evaluation of tedizolid for the treatment of MRSA infections

(2018) Ronald G. Hall et al.   EXPERT OPINION ON PHARMACOTHERAPY

The prodrug approach in the era of drug design

(2018) Anas Najjar et al.   Expert Opinion on Drug Delivery

Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections

(2017) Darrell McBride et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma

(2017) Marco Salvini et al.   Expert Opinion on Drug Metabolism & Toxicology

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

(2017) William D Tap et al.   LANCET ONCOLOGY

Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction

(2017) Lauren G. Gilstrap et al.   Journal of the American Heart Association

Evofosfamide, a new horizon in the treatment of pancreatic cancer

(2016) Mohsen Pourmorteza et al.   ANTI-CANCER DRUGS

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

(2016) Ruben T. H. M. Larue et al.   BMC CANCER

Telotristat ethyl: a new option for the management of carcinoid syndrome

(2016) Angela Lamarca et al.   EXPERT OPINION ON PHARMACOTHERAPY

A minireview on N -acetylcysteine: An old drug with new approaches

(2016) Ines Elbini Dhouib et al.   LIFE SCIENCES

Primary Open-Angle Glaucoma Preferred Practice Pattern® Guidelines

(2016) Bruce E. Prum et al.   OPHTHALMOLOGY

Cardiovascular Safety Pharmacology of Sibutramine

(2015) Jaesuk Yun et al.   Biomolecules & Therapeutics

Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel

(2015) Xi-Ling Jiang et al.   CLINICAL PHARMACOKINETICS

Sacubitril/Valsartan (Entresto) for Heart Failure

(2015)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anti-viral therapy for congenital cytomegalovirus infection: pharmacokinetics, efficacy and side effects

(2015) Arianna Mareri et al.   Journal of Maternal-Fetal & Neonatal Medicine

Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish population-based study

(2015) Elisabeth Svensson et al.   Clinical Epidemiology

First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma

(2015) Sant P. Chawla et al.   JAMA Oncology

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma

(2014) Sant P. Chawla et al.   CANCER

Patterns of Statin Initiation, Intensification, and Maximization Among Patients Hospitalized With an Acute Myocardial Infarction

(2014) Suzanne V. Arnold et al.   CIRCULATION

Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C

(2014) Gillian M. Keating   DRUGS

Using predrugs to optimize drug candidates

(2014) Rafik Karaman   Expert Opinion on Drug Discovery

Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran

(2014) Harry Southworth   STATISTICS IN MEDICINE

Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil

(2013) Chao Chen   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

(2013) Kris V Kowdley et al.   LANCET

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

(2013) Eric Lawitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies

(2012) Muhammad Baluom et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?

(2012) Hua Rong Lu et al.   BRITISH JOURNAL OF PHARMACOLOGY

Lisdexamfetamine Dimesylate

(2012) Christopher Steer et al.   CNS DRUGS

Aripiprazole

(2012) Jamie D. Croxtall   CNS DRUGS

Interferon-Free Hepatitis C Therapy

(2012) Paul J. Pockros   DRUGS

Studies on the Metabolism and Biological Activity of the Epimers of Sulindac

(2011) D. Brunell et al.   DRUG METABOLISM AND DISPOSITION

Aripiprazole

(2011) Sohita Dhillon   DRUGS

Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation

(2010) D. J. Sweeny et al.   DRUG METABOLISM AND DISPOSITION

Codrug: An efficient approach for drug optimization

(2010) N. Das et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Pharmacokinetic evaluation of fosaprepitant dimeglumine

(2010) Francheska Colon-Gonzalez et al.   Expert Opinion on Drug Metabolism & Toxicology

Leflunomide: a drug with a potential beyond rheumatology

(2010) Sven Teschner et al.   Immunotherapy

Pharmacokinetics of Acyclovir and Its Metabolites in Cerebrospinal Fluid and Systemic Circulation after Administration of High-Dose Valacyclovir in Subjects with Normal and Impaired Renal Function

(2009) J. P. Smith et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Balsalazide in treating colonic diseases

(2009) Antonio Tursi   Expert Opinion on Drug Metabolism & Toxicology

Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs

(2008) Jian-Xin Duan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Prodrugs in Cardiovascular Therapy

(2008) Marinella Sandros et al.   MOLECULES